Showing results (51-60 of 101) with videos related to

Sort By:
Pageof 11
Journal of Oncology Practice|August 7, 2019
Immune-Related Adverse Events Requiring Hospitalization: Spectrum of Toxicity, Treatment, and OutcomesAanika Balaji, Jiajia Zhang, Beatriz Wills, et al.
Genome Biology|May 14, 2021
Multi-omic profiling of lung and liver tumor microenvironments of metastatic pancreatic cancer reveals site-specific immune regulatory pathwaysWon Jin Ho, Rossin Erbe, Ludmila Danilova, et al.
Scientific Reports|January 14, 2025
Targeted dual biologic therapy for erythroderma of unknown etiology guided by high-parameter peripheral blood immunophenotypingHannah L Cornman, Martin P Alphonse, Arbor Dykema, et al.
Biorxiv : the Preprint Server for Biology|July 29, 2024
High-motility pro-tumorigenic monocytes drive macrophage enrichment in the tumor microenvironmentWenxuan Du, Bryan Zhou, André Forjaz, et al.
Biorxiv : the Preprint Server for Biology|February 13, 2023
Single-cell RNA sequencing reveals dysregulated fibroblast subclusters in prurigo nodularisJay R Patel, Marina Z Joel, Kevin K Lee, et al.
Hepatology (Baltimore, Md.)|August 9, 2022
Profiling of syngeneic mouse HCC tumor models as a framework to understand anti-PD-1 sensitive tumor microenvironmentsDaniel J Zabransky, Ludmila Danilova, James M Leatherman, et al.
Biorxiv : the Preprint Server for Biology|February 7, 2023
Reprogramming Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti-PD1 TherapyJiang Chen, Zohreh Amoozgar, Xin Liu, et al.
Cell Reports. Medicine|February 2, 2024
Multimodal immune phenotyping reveals microbial-T cell interactions that shape pancreatic cancerYan Li, Renee B Chang, Meredith L Stone, et al.
Biorxiv : the Preprint Server for Biology|August 16, 2024
3D histology reveals that immune response to pancreatic precancers is heterogeneous and depends on global pancreas structureAshley L Kiemen, Cristina Almagro-Pérez, Valentina Matos, et al.
Cancer Immunology Research|January 12, 2026
A randomized phase II study: CRS207/GVAX plus anti-PD1 and anti-CTLA4 recruits mesothelin- and mKRAS-specific T cells into PDACKatherine M Bever, Amanda L Huff, Ludmila Danilova, et al.
Pageof 11